Establishment and optimization of a molecular marker-based survival prediction scoring system for postoperative hepatocellular carcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400088817

Enrollment

Unknown

Registered

2024-08-27

Start date

2024-08-31

Completion date

Unknown

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

None:None

Eligibility

Sex/Gender

All

Age

30 Years to 85 Years

Inclusion criteria

Inclusion criteria: ?Patients diagnosed with hepatocellular carcinoma; ?No preoperative systemic chemotherapy or local radiotherapy; ?No preoperative catheterized intra-arterial chemoembolization, anhydrous alcohol intratumoral injection, and radiofrequency ablation; ?Have an indication for surgery and can tolerate radical surgical resection for hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: ?Severe cardiovascular disease, uncontrolled infection, or other uncontrolled co-morbidities; ?Subjects or family members were unable to understand the conditions and objectives of this study; ?Received an organ transplant, stem cell transplant, bone marrow transplant, or received a blood transfusion in the month prior to enrollment; ?Occurrence of non-tumor-related death or death within 30 days of surgery

Design outcomes

Primary

Measure	Time frame
Overall survival ;Disease fress survival;	—

Countries

China

Contacts

Public ContactShengsen Chen

Zhejiang Cancer Hospital

chenss@zjcc.org.cn+86 151 6710 3088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026